Literature DB >> 16086422

Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS).

P Imbach1, T Kühne, D Müller, W Berchtold, S Zimmerman, M Elalfy, G R Buchanan.   

Abstract

BACKGROUND: Acute and chronic idiopathic thrombocytopenic purpura (ITP) is traditionally based on the duration of thrombocytopenia at the cut-off point of 6 months after diagnosis. Registry I evaluated the diagnosis, definition, management, and follow-up of childhood ITP. This report focuses on children with thrombocytopenia persisting more than 6 months. PROCEDURE: Data were collected by questionnaires to the physicians caring for children with ITP, at diagnosis, 6, and 12 months later. Data were compared regarding initial features and follow-up with emphasis on children with persistent thrombocytopenia, and those with ITP who recovered their platelet counts between 7 and 12 months from diagnosis.
RESULTS: At 12 months from diagnosis, 79 of 308 (25.6%) evaluable children recovered from ITP and 229 had ongoing ITP. Children with recovered ITP were younger than children with ongoing ITP (P = 0.043) and exhibited a lower frequency of bleeding symptoms during the first 6 months after diagnosis (P = 0.018). Frequency of hospitalization, bone marrow aspiration, and drug treatment differed regionally.
CONCLUSIONS: The high rate of recovery from ITP between 7 to 12 months demonstrates, that the cut-off point of 6 months for the definition of chronic ITP does not adequately differentiate chronic from acute ITP. The majority of children with ITP have variable time to recovery with gradual improvement of platelet counts and disappearance of bleeding signs. ITP is a heterogeneous disorder with a diverse natural history and diverse pattern of treatment response.

Entities:  

Mesh:

Year:  2006        PMID: 16086422     DOI: 10.1002/pbc.20453

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  31 in total

Review 1.  Novel clearance mechanisms of platelets.

Authors:  Renata Grozovsky; Karin M Hoffmeister; Hervé Falet
Journal:  Curr Opin Hematol       Date:  2010-11       Impact factor: 3.284

2.  Physician decision making in selection of second-line treatments in immune thrombocytopenia in children.

Authors:  Rachael F Grace; Jenny M Despotovic; Carolyn M Bennett; James B Bussel; Michelle Neier; Cindy Neunert; Shelley E Crary; Yves D Pastore; Robert J Klaassen; Jennifer A Rothman; Kerry Hege; Vicky R Breakey; Melissa J Rose; Kristin A Shimano; George R Buchanan; Amy Geddis; Kristina M Haley; Adonis Lorenzana; Alexis Thompson; Michael Jeng; Ellis J Neufeld; Travis Brown; Peter W Forbes; Michele P Lambert
Journal:  Am J Hematol       Date:  2018-05-06       Impact factor: 10.047

3.  Applicability of 2009 international consensus terminology and criteria for immune thrombocytopenia to a clinical pediatric population.

Authors:  Rachael F Grace; Michelle Long; Leslie A Kalish; Ellis J Neufeld
Journal:  Pediatr Blood Cancer       Date:  2011-06-14       Impact factor: 3.167

4.  Comparative of three methods (ELIZA, MAIPA and flow cytometry) to determine anti-platelet antibody in children with ITP.

Authors:  Mohsen Hamidpour; Ghader Khalili; Nader Tajic; Bi Bi Shahin Shamsian; Rafie Hamidpour
Journal:  Am J Blood Res       Date:  2014-12-15

Review 5.  Clinical practice: immune thrombocytopenia in paediatrics.

Authors:  Veerle Labarque; Chris Van Geet
Journal:  Eur J Pediatr       Date:  2014-01-05       Impact factor: 3.183

6.  A characteristic flow cytometric pattern with broad forward scatter and narrowed side scatter helps diagnose immune thrombocytopenia (ITP).

Authors:  Raita Araki; Ryosei Nishimura; Rie Kuroda; Toshihiro Fujiki; Shintaro Mase; Kazuhiro Noguchi; Yasuhiro Ikawa; Hideaki Maeba; Akihiro Yachie
Journal:  Int J Hematol       Date:  2018-04-16       Impact factor: 2.490

7.  Determining a definite diagnosis of primary immune thrombocytopenia by medical record review.

Authors:  Deirdra R Terrell; Laura A Beebe; Sara K Vesely; Barbara R Neas; Jodi B Segal; James N George
Journal:  Am J Hematol       Date:  2012-06-20       Impact factor: 10.047

8.  B-cell hyperfunction in children with immune thrombocytopenic purpura persists after splenectomy.

Authors:  Paola Giordano; Simona Cascioli; Giuseppe Lassandro; Valentina Marcellini; Fabio Cardinale; Federica Valente; Franco Locatelli; Rita Carsetti
Journal:  Pediatr Res       Date:  2015-10-22       Impact factor: 3.756

9.  Identification of predictive factors for response to intravenous immunoglobulin treatment in children with immune thrombocytopenia.

Authors:  Yoshihito Morimoto; Nao Yoshida; Nozomu Kawashima; Kimikazu Matsumoto; Koji Kato
Journal:  Int J Hematol       Date:  2014-02-27       Impact factor: 2.490

10.  Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura.

Authors:  Cindy E Neunert; George R Buchanan; Paul Imbach; Paula H B Bolton-Maggs; Carolyn M Bennett; Ellis J Neufeld; Sara K Vesely; Leah Adix; Victor S Blanchette; Thomas Kühne
Journal:  Blood       Date:  2008-08-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.